Lexeo Reports Interim PKP2 Gene Therapy Data

Company Lexeo Therapeutics Event Type Interim Phase 1/2 data Modality AAVrh10 gene therapy Asset LX2020 Target PKP2 gene replacement Disease Area PKP2 arrhythmogenic cardiomyopathy Summary Lexeo reported interim single-arm Phase 1/2 LX2020 data in PKP2 arrhythmogenic cardiomyopathy. Seven high-dose participants had an 80% mean reduction…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *